[The state and perspective in bone regeneration].
Treatments for locomotive organs, such as bone and joint, have been investigated and preceded in recent decades. Especially, in orthopaedic field, therapeutic alternatives for total joint arthroplasty for osteoarthritis and spinal fusion have remarkably advanced. However, bone regeneration required in massive bone defect or broad spinal fusion have been treated with bone graft mainly using auto grafted bone here in Japan. These methods have several issues such as limited bone regeneration or pain in harvest sites. We would like to describe perspectives and biology in bone regeneration focusing on bone morphogenetic protein (BMP).
Imai
Yuuki
Y
Osaka City University Graduate School of Medicine, Department of Orthopaedic Surgery, Japan.
Takaoka
Kunio
K
D000818:Animals; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D001861:Bone Regeneration / Q000187:drug effects / Q000502:physiology; D002454:Cell Differentiation / Q000187:drug effects; D004337:Drug Carriers; D006801:Humans; D019344:Lactic Acid; D010006:Osteoblasts / Q000166:cytology; D010726:Phosphodiesterase Inhibitors; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011994:Recombinant Proteins / Q000627:therapeutic use; D044968:Regenerative Medicine / Q000379:methods / Q000639:trends; D013268:Stimulation, Chemical; D023822:Tissue Engineering
D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D010726:Phosphodiesterase Inhibitors; D011994:Recombinant Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid